ProBioGen and Ceva Santé Animale Sign an Exclusive License Agreement to Produce Vectorised Poultry Vaccines Using AGE1.CR® Production Technology
BERLIN, Germany and LIBOURNE, France, October 1st, 2019 / B3C newswire / -- ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.
ProBioGen and Ceva have a long track record of producing innovative veterinary vaccine technologies from a number of different research and development programs.
Dr. Volker Sandig, Chief Scientific Officer of ProBioGen, said: “This agreement is a cumulation of our collaboration. It is highly satisfying that in this relationship our technology will contribute to leading veterinary vaccines and will cement a unique advantage for a modern production process for important animal diseases.”
Dr. Pascal Anjot, Ceva’s Innovation and Development Director, said: “The AGE1.CR® technology has proved its versatility and value in the animal health sector. We are delighted to have entered into a new phase of our relationship with ProBioGen, which fits perfectly with our strategy of promoting innovation both internally and together with the best-in-class external partners.”
Dr. Wieland Wolf, Chief Executive Officer of ProBioGen, added: “Although the focus of ProBioGen is on human biotherapeutics we are excited to work also with global animal health companies. Here we leveraged the competitive expertise of our virology department by developing fully scalable, robust, flexible and economical production technologies”.